SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia

Srdan Verstovsek, Norio Komatsu, Harinder Gill, Jie Jin, Sung Eun Lee, Hsin An Hou, Toshiaki Sato, Albert Qin, Raymond Urbanski, Weichung Shih, Oleh Zagrijtschuk, Craig Zimmerman, Ruben A. Mesa

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

Patients diagnosed with high-risk essential thrombocythemia (ET) have limited treatment options to reduce the risk of thrombosis and lessen the progression of the disease by targeting the molecular source. Hydroxyurea is the recommended treatment, but many patients experience resistance or intolerance. Anagrelide is an approved second-line option for ET, but concerns of a higher frequency of disease transformation may affect its role as a suitable long-term option. Interferons have been evaluated in myeloproliferative neoplasms for over 30 years, but early formulations had safety and tolerability issues. SURPASS-ET (NCT04285086) is a phase III, open-label, multicenter, global, randomized, active-controlled trial that will evaluate the safety, efficacy, tolerability and pharmacokinetics of ropeginterferon alfa-2b compared with anagrelide as second-line therapy in high-risk ET.

Original languageEnglish (US)
Pages (from-to)2999-3009
Number of pages11
JournalFuture Oncology
Volume18
Issue number27
DOIs
StatePublished - Sep 1 2022

Keywords

  • P1101
  • SURPASS-ET
  • anagrelide
  • essential thrombocythemia
  • hydroxyurea
  • interferon
  • myeloproliferative neoplasm
  • pegylated interferon
  • ropeginterferon alfa-2b

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia'. Together they form a unique fingerprint.

Cite this